A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

NCT07083739 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Thrombocytopenia

Interventions

DRUG: TQB3473 Tablets

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.